NewAmsterdam Pharma Co N.V. SEC filings NAMSW

NewAmsterdam Pharma Co N.V. has 415 filings in SEC EDGAR's recent list, going back to Aug 4, 2022. Its latest annual report, Form ARS, was filed on May 6, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Nov 4, 2026, covering the quarter ended Sep 30, 2026. The most recent current report (Form 8-K) was filed on Nov 4, 2026. The company's fiscal year ends on December 31.

NewAmsterdam Pharma Co N.V. SEC filings
Form Description Filed Period
SCHEDULE 13G/A Amended ownership over 5% (passive) Nov 5, 2026 —
10-Q Quarterly report Nov 4, 2026 Sep 30, 2026
8-K Current report Nov 4, 2026 Nov 4, 2026
4 Insider transaction Oct 2, 2026 Sep 30, 2026
8-K Current report
Other events
Sep 29, 2026 Sep 29, 2026
SCHEDULE 13D/A Amended ownership over 5% (active) Sep 22, 2026 —
8-K Current report
Other events
Sep 21, 2026 Sep 21, 2026
4 Insider transaction Sep 15, 2026 Sep 14, 2026
4 Insider transaction Sep 9, 2026 Sep 4, 2026
4 Insider transaction Sep 3, 2026 Sep 1, 2026
144/A Filing Aug 25, 2026 —
4 Insider transaction Aug 25, 2026 Aug 24, 2026
144 Notice of proposed sale Aug 24, 2026 —
8-K/A Amended current report
Officer or director change
Aug 14, 2026 Jul 16, 2026
3 Initial insider ownership Aug 14, 2026 Aug 10, 2026
8-K Current report
Officer or director change
Aug 14, 2026 Aug 10, 2026
SCHEDULE 13G/A Amended ownership over 5% (passive) Aug 6, 2026 —
8-K Current report
Results of operations
Aug 5, 2026 Aug 5, 2026
10-Q Quarterly report Aug 5, 2026 Jun 30, 2026
8-K Current report
Other events
Jul 24, 2026 Jul 24, 2026
8-K Current report
Officer or director change
Jul 22, 2026 Jul 16, 2026
4 Insider transaction Jul 22, 2026 Jul 20, 2026
4 Insider transaction Jun 24, 2026 Jun 22, 2026
S-8 Employee stock plan registration Jun 5, 2026 —
SCHEDULE 13G/A Amended ownership over 5% (passive) Jun 4, 2026 —
8-K Current report
Officer or director change, Shareholder vote results
Jun 3, 2026 Jun 2, 2026
4 Insider transaction May 27, 2026 May 26, 2026
144 Notice of proposed sale May 26, 2026 —
SCHEDULE 13D/A Amended ownership over 5% (active) May 14, 2026 —
8-K Current report
Results of operations
May 7, 2026 May 7, 2026
10-Q Quarterly report May 7, 2026 Mar 31, 2026
SCHEDULE 13G/A Amended ownership over 5% (passive) May 6, 2026 —
ARS Annual report to shareholders May 6, 2026 Dec 31, 2025
DEF 14A Proxy statement May 6, 2026 May 6, 2026
8-K Current report
Officer or director change
Apr 24, 2026 Apr 20, 2026
PRE 14A Preliminary proxy statement Apr 20, 2026 Apr 20, 2026
4 Insider transaction Mar 12, 2026 Mar 11, 2026
144 Notice of proposed sale Mar 11, 2026 —
4 Insider transaction Mar 10, 2026 Mar 6, 2026
4 Insider transaction Mar 9, 2026 Mar 5, 2026
144 Notice of proposed sale Mar 6, 2026 —
144 Notice of proposed sale Mar 5, 2026 —
4 Insider transaction Mar 2, 2026 Mar 2, 2026
144 Notice of proposed sale Mar 2, 2026 —
8-K Current report
Regulation FD disclosure
Mar 2, 2026 Mar 2, 2026
4 Insider transaction Feb 26, 2026 Feb 24, 2026
4 Insider transaction Feb 24, 2026 Feb 20, 2026
144 Notice of proposed sale Feb 24, 2026 —
144 Notice of proposed sale Feb 20, 2026 —
S-8 Employee stock plan registration Feb 18, 2026 —
10-K Annual report Feb 18, 2026 Dec 31, 2025
8-K Current report
Results of operations
Feb 18, 2026 Feb 18, 2026
SCHEDULE 13G/A Amended ownership over 5% (passive) Feb 17, 2026 —
SCHEDULE 13G Ownership over 5% (passive) Feb 5, 2026 —
4 Insider transaction Jan 29, 2026 Jan 27, 2026
4 Insider transaction Jan 27, 2026 Jan 23, 2026
4 Insider transaction Jan 22, 2026 Jan 20, 2026
144 Notice of proposed sale Jan 20, 2026 —
4 Insider transaction Jan 9, 2026 Jan 7, 2026
4 Insider transaction Jan 9, 2026 Jan 7, 2026
4 Insider transaction Jan 9, 2026 Jan 7, 2026
4 Insider transaction Jan 9, 2026 Jan 7, 2026
4 Insider transaction Jan 9, 2026 Jan 7, 2026
4 Insider transaction Jan 9, 2026 Jan 7, 2026
4 Insider transaction Jan 9, 2026 Jan 7, 2026
8-K Current report
Results of operations, Regulation FD disclosure
Jan 9, 2026 Jan 9, 2026
4 Insider transaction Jan 7, 2026 Jan 5, 2026
4 Insider transaction Jan 7, 2026 Jan 5, 2026
4 Insider transaction Jan 7, 2026 Jan 5, 2026
144 Notice of proposed sale Jan 7, 2026 —
144 Notice of proposed sale Jan 6, 2026 —
144 Notice of proposed sale Jan 5, 2026 —
144 Notice of proposed sale Jan 5, 2026 —
144 Notice of proposed sale Jan 5, 2026 —
4 Insider transaction Dec 29, 2025 Dec 23, 2025
144 Notice of proposed sale Dec 23, 2025 —
SCHEDULE 13D/A Amended ownership over 5% (active) Dec 4, 2025 —
144 Notice of proposed sale Dec 2, 2025 —
144 Notice of proposed sale Dec 2, 2025 —
144 Notice of proposed sale Dec 2, 2025 —
SCHEDULE 13G/A Amended ownership over 5% (passive) Nov 13, 2025 —
SCHEDULE 13D/A Amended ownership over 5% (active) Nov 7, 2025 —
10-Q Quarterly report Nov 5, 2025 Sep 30, 2025
8-K Current report
Results of operations, Regulation FD disclosure
Nov 5, 2025 Nov 5, 2025
SCHEDULE 13D/A Amended ownership over 5% (active) Nov 4, 2025 —
SCHEDULE 13D/A Amended ownership over 5% (active) Sep 30, 2025 —
4 Insider transaction Sep 17, 2025 Sep 15, 2025
4 Insider transaction Sep 10, 2025 Sep 9, 2025
4 Insider transaction Sep 10, 2025 Sep 8, 2025
144 Notice of proposed sale Sep 9, 2025 —
4 Insider transaction Sep 5, 2025 Sep 3, 2025
4 Insider transaction Sep 4, 2025 Sep 2, 2025
144 Notice of proposed sale Sep 3, 2025 —
8-K Current report
Regulation FD disclosure
Sep 2, 2025 Sep 2, 2025
4 Insider transaction Aug 27, 2025 Aug 25, 2025
144 Notice of proposed sale Aug 27, 2025 —
4 Insider transaction Aug 25, 2025 Aug 21, 2025
144 Notice of proposed sale Aug 25, 2025 —
SCHEDULE 13D/A Amended ownership over 5% (active) Aug 20, 2025 —
8-K Current report
Regulation FD disclosure, Other events
Aug 18, 2025 Aug 18, 2025
8-K Current report
Material agreement
Aug 15, 2025 Aug 12, 2025
4 Insider transaction Aug 13, 2025 Aug 11, 2025
SCHEDULE 13G/A Amended ownership over 5% (passive) Aug 13, 2025 —
SCHEDULE 13D/A Amended ownership over 5% (active) Aug 12, 2025 —
8-K Current report
Results of operations
Aug 6, 2025 Aug 6, 2025
10-Q Quarterly report Aug 6, 2025 Jun 30, 2025
8-K Current report
Regulation FD disclosure, Other events
Jul 30, 2025 Jul 30, 2025
4 Insider transaction Jul 17, 2025 Jul 15, 2025
144 Notice of proposed sale Jul 14, 2025 —
8-K Current report
Officer or director change
Jul 11, 2025 Jul 11, 2025
4 Insider transaction Jun 26, 2025 Jun 24, 2025
4 Insider transaction Jun 18, 2025 Jun 16, 2025
4 Insider transaction Jun 18, 2025 Jun 16, 2025
144 Notice of proposed sale Jun 18, 2025 —
8-K Current report
Regulation FD disclosure
Jun 11, 2025 Jun 11, 2025
8-K Current report
Regulation FD disclosure, Other events
Jun 9, 2025 Jun 9, 2025
8-K Current report
Shareholder vote results
Jun 6, 2025 Jun 4, 2025
4 Insider transaction Jun 3, 2025 Jun 1, 2025
4 Insider transaction Jun 3, 2025 Jun 1, 2025
3 Initial insider ownership Jun 3, 2025 May 27, 2025
4 Insider transaction May 19, 2025 May 15, 2025
SCHEDULE 13G/A Amended ownership over 5% (passive) May 15, 2025 —
144 Notice of proposed sale May 15, 2025 —
SCHEDULE 13G Ownership over 5% (passive) May 13, 2025 —
ARS Annual report to shareholders May 8, 2025 Dec 31, 2024
DEF 14A Proxy statement May 8, 2025 Jun 4, 2025
10-Q Quarterly report May 8, 2025 Mar 31, 2025
8-K Current report
Results of operations
May 8, 2025 May 8, 2025
8-K Current report
Regulation FD disclosure, Other events
May 7, 2025 May 7, 2025
4 Insider transaction May 2, 2025 May 1, 2025
4 Insider transaction May 2, 2025 May 1, 2025
PRE 14A Preliminary proxy statement Apr 28, 2025 Jun 4, 2025
4 Insider transaction Apr 21, 2025 Apr 14, 2025
4 Insider transaction Apr 17, 2025 Apr 15, 2025
4 Insider transaction Apr 17, 2025 Apr 15, 2025
3 Initial insider ownership Apr 17, 2025 Apr 15, 2025
8-K Current report
Officer or director change, Regulation FD disclosure
Apr 17, 2025 Apr 15, 2025
144 Notice of proposed sale Apr 11, 2025 —
4 Insider transaction Mar 28, 2025 Mar 26, 2025
4 Insider transaction Mar 28, 2025 Mar 26, 2025
4 Insider transaction Mar 28, 2025 Mar 26, 2025
4 Insider transaction Mar 28, 2025 Mar 26, 2025
4 Insider transaction Mar 28, 2025 Mar 26, 2025
4 Insider transaction Mar 28, 2025 Mar 26, 2025
144 Notice of proposed sale Mar 26, 2025 —
144 Notice of proposed sale Mar 26, 2025 —
4 Insider transaction Mar 26, 2025 Mar 24, 2025
4 Insider transaction Mar 19, 2025 Mar 17, 2025
EFFECT Filing Mar 10, 2025 —
424B3 Prospectus Mar 10, 2025 —
4 Insider transaction Mar 6, 2025 Mar 4, 2025
CORRESP Letter to the SEC Mar 6, 2025 —
4 Insider transaction Mar 5, 2025 Mar 4, 2025
144 Notice of proposed sale Mar 4, 2025 —
UPLOAD Letter from the SEC Mar 4, 2025 —
S-3 Shelf registration Feb 28, 2025 —
10-K Annual report Feb 26, 2025 Dec 31, 2024
8-K Current report
Results of operations
Feb 26, 2025 Feb 26, 2025
4 Insider transaction Feb 20, 2025 Feb 18, 2025
SCHEDULE 13G/A Amended ownership over 5% (passive) Feb 14, 2025 —
SCHEDULE 13G/A Amended ownership over 5% (passive) Feb 14, 2025 —
4 Insider transaction Jan 31, 2025 Jan 29, 2025
4 Insider transaction Jan 29, 2025 Jan 27, 2025
4 Insider transaction Jan 29, 2025 Jan 27, 2025
144 Notice of proposed sale Jan 27, 2025 —
144 Notice of proposed sale Jan 27, 2025 —
144 Notice of proposed sale Jan 10, 2025 —
8-K Current report
Regulation FD disclosure
Jan 10, 2025 Jan 10, 2025
4 Insider transaction Jan 8, 2025 Jan 6, 2025
4 Insider transaction Jan 8, 2025 Jan 6, 2025
4 Insider transaction Jan 8, 2025 Jan 6, 2025
4 Insider transaction Jan 8, 2025 Jan 6, 2025
4 Insider transaction Jan 8, 2025 Jan 6, 2025
4 Insider transaction Jan 7, 2025 Jan 7, 2025
4 Insider transaction Jan 7, 2025 Jan 6, 2025
4 Insider transaction Jan 7, 2025 Jan 7, 2025
4 Insider transaction Jan 7, 2025 Jan 7, 2025
4 Insider transaction Jan 7, 2025 Jan 7, 2025
4 Insider transaction Jan 7, 2025 Jan 7, 2025
4 Insider transaction Jan 7, 2025 Jan 7, 2025
S-8 Employee stock plan registration Jan 7, 2025 —
4 Insider transaction Jan 6, 2025 Jan 2, 2025
4 Insider transaction Jan 6, 2025 Jan 2, 2025
4 Insider transaction Jan 6, 2025 Jan 2, 2025
4 Insider transaction Jan 6, 2025 Jan 2, 2025
4 Insider transaction Jan 6, 2025 Jan 2, 2025
4 Insider transaction Jan 6, 2025 Jan 2, 2025
4 Insider transaction Jan 2, 2025 Dec 30, 2024
4 Insider transaction Dec 30, 2024 Dec 26, 2024
4 Insider transaction Dec 26, 2024 Dec 20, 2024
4 Insider transaction Dec 20, 2024 Dec 18, 2024
4 Insider transaction Dec 18, 2024 Dec 16, 2024
SC 13D/A Amended ownership over 5% (active) Dec 17, 2024 —
4 Insider transaction Dec 17, 2024 Dec 13, 2024
SC 13D/A Amended ownership over 5% (active) Dec 17, 2024 —
SC 13D/A Amended ownership over 5% (active) Dec 17, 2024 —
4 Insider transaction Dec 16, 2024 Dec 12, 2024
8-K Current report
Material agreement, Regulation FD disclosure
Dec 13, 2024 Dec 11, 2024
424B5 Prospectus supplement Dec 13, 2024 —
4 Insider transaction Dec 12, 2024 Dec 10, 2024

Showing 200 filings, the most recent 200. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.

Company profile

Industry
Pharmaceutical Preparations (SIC 2834)
Listed as
NAMS (Nasdaq), NAMSW (Nasdaq)
Fiscal year ends
December 31
Incorporated in
Netherlands
Headquarters
Narrden, Netherlands
SEC filer status
Large accelerated filer
SEC CIK
1936258
Former names
NewAmsterdam Pharma Co B.V. (until Nov 22, 2022)

Other Pharmaceutical Preparations companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.